Sterile Capacity Expansion Halo Pharma is launching sterile injectable manufacturing at its Whippany facility and expanding qualification to support clients' sterile fill needs. A strategic partnership with Apotex secures a substantial portion of the sterile filling capacity under development, signaling strong demand and creating a ready pipeline for new sterile programs.

Integrated NA Supply As part of Normaco Group with Noramco and Purisys, Halo offers an end-to-end North American supply chain for clinical and commercial APIs through to drug products, enabling customers to consolidate vendors and streamline sourcing.

Cross-Border Footprint Halo operates in Whippany and Montreal and plans further expansion in New Jersey and across North America, including a Mirabel site, which supports cross-border manufacturing and regional delivery for US and Canadian customers.

BFS Capabilities Halo is developing BFS products and providing sterile development and manufacturing across diagnostics, respiratory, ophthalmic, topical and other applications, offering clients a capable platform for BFS programs and rapid scale-up.

Leadership Momentum Leadership changes and new appointments, including a CEO hire and site leadership, underscore a growth-focused strategy and active business development, creating a stable environment for long-term CDMO partnerships.